<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: Continuous positive airway pressure (CPAP) is the first-line treatment for patients with symptomatic <z:hpo ids='HP_0002870'>obstructive sleep apnea</z:hpo> (OSA) </plain></SENT>
<SENT sid="1" pm="."><plain>However, its indication for <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">sleep-disordered breathing</z:e>, regardless of daytime symptoms, is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To evaluate the effect of CPAP treatment on the incidence of <z:hpo ids='HP_0000822'>hypertension</z:hpo> or cardiovascular events in a cohort of nonsleepy patients with OSA </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN, SETTING, AND PATIENTS: Multicenter, parallel-group, randomized controlled trial in 14 teaching hospitals in Spain </plain></SENT>
<SENT sid="4" pm="."><plain>Between May 2004 and May 2006, 725 consecutive patients were enrolled who had an <z:hpo ids='HP_0002104'>apnea</z:hpo>-<z:mp ids='MP_0001956'>hypopnea</z:mp> index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from 0-24, with values &lt;10 suggesting no daytime sleepiness) </plain></SENT>
<SENT sid="5" pm="."><plain>Exclusion criteria were previous cardiovascular event, physical or psychological incapacity, <z:hpo ids='HP_0011010'>chronic</z:hpo> disease, or drug or alcohol <z:mp ids='MP_0002555'>addiction</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Follow-up ended in May 2009 </plain></SENT>
<SENT sid="7" pm="."><plain>INTERVENTION: Patients were allocated to receive CPAP treatment or no active intervention </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> participants received dietary counseling and sleep hygiene advice </plain></SENT>
<SENT sid="9" pm="."><plain>MAIN OUTCOME MEASURES: Incidence of either <z:hpo ids='HP_0000822'>systemic hypertension</z:hpo> (taking <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> medication or blood pressure greater than 140/90 mm Hg) or cardiovascular event (nonfatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, nonfatal <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, hospitalization for unstable <z:mp ids='MP_0006112'>angina</z:mp> or <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, or cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>) </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: Seven hundred twenty-three patients underwent follow-up for a median of 4 (interquartile range, 2.7-4.4) years (1 patient from each group did not receive allocated treatment); 357 in the CPAP group and 366 in the control group were included in the analysis </plain></SENT>
<SENT sid="11" pm="."><plain>In the CPAP group there were 68 patients with new <z:hpo ids='HP_0000822'>hypertension</z:hpo> and 28 cardiovascular events (17 unstable <z:mp ids='MP_0006112'>angina</z:mp> or <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, 3 nonfatal <z:hpo ids='HP_0001297'>stroke</z:hpo>, 3 <z:hpo ids='HP_0001635'>heart failure</z:hpo>, 2 nonfatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, 2 <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, 1 cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>) </plain></SENT>
<SENT sid="12" pm="."><plain>In the control group there were 79 patients with new <z:hpo ids='HP_0000822'>hypertension</z:hpo> and 31 cardiovascular events (11 unstable <z:mp ids='MP_0006112'>angina</z:mp> or <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, 8 nonfatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, 5 <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, 5 <z:hpo ids='HP_0001635'>heart failure</z:hpo>, 2 nonfatal <z:hpo ids='HP_0001297'>stroke</z:hpo>) </plain></SENT>
<SENT sid="13" pm="."><plain>The <z:hpo ids='HP_0000822'>hypertension</z:hpo> or cardiovascular event incidence density rate was 9.20 per 100 person-years (95% CI, 7.36-11.04) in the CPAP group and 11.02 per 100 person-years (95% CI, 8.96-13.08) in the control group </plain></SENT>
<SENT sid="14" pm="."><plain>The incidence density ratio was 0.83 (95% CI, 0.63-1.1; P = .20) </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: In patients with OSA without daytime sleepiness, the prescription of CPAP compared with usual care did not result in a statistically significant reduction in the incidence of <z:hpo ids='HP_0000822'>hypertension</z:hpo> or cardiovascular events </plain></SENT>
<SENT sid="16" pm="."><plain>However, the study may have had limited power to detect a significant difference </plain></SENT>
<SENT sid="17" pm="."><plain>TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00127348 </plain></SENT>
</text></document>